https://www.selleckchem.com/pr....oducts/crenolanib-cp
In Part B, 13 of 15 enrolled patients had high-grade NETs. Of these, one had PR, and four had SD for more than 10 months. The combination of alisertib and nab-paclitaxel has manageable side-effect profile and showed promising preliminary efficacy in high-grade NETs, warranting further testing. ClinicalTrials.gov identifier NCT01677559. ClinicalTrials.gov identifier NCT01677559. Chondroprogenitors display promise for articular cartilage regeneration. It is imperative to standardize culture conditions, to further enhance chon
Like
Comment
Share
